Kalaris Therapeutics, Inc.
KLRS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001754068
No open-market purchases or sales by Kalaris Therapeutics, Inc. insiders were filed in the last 90 days; 56 institutions reported holding it in 13F filings for Q2 2026, worth $73.4M in total; no superinvestor holds it.
Holders of 5% or more of KLRS
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Kalaris Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Samsara BioCapital, L.P. | 13D/A | 54.20%12.9M shares | −2.30 ppfrom 56.50% | Mar 25, 20254 filings | May 22, 2026 | SEC |
| RTW Investments, LP | 13G | 5.70%1.30M shares | New | Feb 17, 20261 filing | Feb 17, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
9 Schedule 13D and 13G filings on Kalaris Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| May 22, 20267:48 PM ET | Samsara BioCapital, L.P.and 4 others | 13D/A | 54.20%12.9M shares | −2.30 ppfrom 56.50% | May 20, 2026 | SEC |
| Feb 17, 20268:14 PM ET | Samsara BioCapital, L.P.and 4 others | 13D/A | 56.50%13.0M shares | 0.00 ppfrom 56.50% | Dec 18, 2025 | SEC |
| Feb 17, 20268:37 AM ET | RTW Investments, LPand 1 other | 13G | 5.70%1.30M shares | New | Dec 31, 2025 | SEC |
| Dec 22, 20254:17 PM ET | Samsara BioCapital, L.P.and 4 others | 13D/A | 56.50%13.0M shares | −4.70 ppfrom 61.20% | Dec 22, 2025 | SEC |
| Jul 29, 20251:21 PM ET | Invus Global Management, LLCand 4 others | 13G/A | 1.50%282.6K shares | –Below 5% | Jun 30, 2025 | SEC |
| May 15, 20252:06 PM ET | EcoR1 Capital, LLCand 2 others | 13G/A | 1.10%201.7K shares | −7.00 ppfrom 8.10%Below 5% | Mar 31, 2025 | SEC |
| Mar 25, 20257:40 PM ET | Samsara BioCapital, L.P.and 2 others | 13D | 61.20%11.4M shares | New | Mar 18, 2025 | SEC |
| Mar 20, 20254:32 PM ET | Gilead Sciences, Inc. | 13G/A | 3.90%723.3K shares | –Below 5% | Mar 18, 2025 | SEC |
| Feb 14, 20251:17 PM ET | EcoR1 Capital, LLCand 2 others | 13G/A | 8.10%408.7K shares | – | Dec 31, 2024 | SEC |
| Feb 9, 2023 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| Aug 8, 2022 | Gilead Sciences, Inc. | 13GOld format | – | New | – | SEC |
| Aug 5, 2022 | Artal International S.C.A. | 13GOld format | – | New | – | SEC |
| Aug 5, 2022 | Globeways Holdings II Ltd | 13DOld format | – | New | – | SEC |
| Aug 5, 2022 | ElevateBio, LLC | 13D/AOld format | – | – | – | SEC |
| Feb 9, 2022 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| Feb 8, 2021 | FMR LLC | 13G/AOld format | – | – | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Kalaris Therapeutics, Inc. shares.
No Form 144 notices for Kalaris Therapeutics, Inc. are on file.